Crism losses widen as it spends on clinical development.
Crism Therapeutics reported a wider full-year loss on Friday, reflecting increased investment in clinical and pre-clinical development as it prepared to start a Phase 2 trial of irinotecan-ChemoSeed in glioblastoma.
Airtel Mobile Commerce N.V. (DI)
26 June 2026 12:43:57
Source: Sharecast
The AIM-traded company said its loss for 2025 widened to £1.90m from £0.61m, with R&D expenditure rising to £908,000.
Total assets were broadly stable at £1.79m, while cash stood at £1.13m at year-end.
During the year, Crism received MHRA clinical trial authorisation for an open-label, registration-grade Phase 2 trial in surgically resectable glioblastoma, and raised £1.93m before expenses through two equity fundraises.
Post year-end, the company secured FDA orphan drug designation for irinotecan-ChemoSeed, a Japanese patent, positive preclinical data for docetaxel-ChemoSeed in prostate cancer, and a further £2.75m before expenses from an oversubscribed fundraise.
It also received Innovate UK and Invest Northern Ireland grants totalling about £1.0m.
Executive chairman Andrew Webb said 2025 was “a year of significant progress”, adding that Crism was “well funded” with a site initiation visit planned for late July, “the final step before patient recruitment begins”.
At 1202 BST, shares in Crism Therapeutics Corporation were flat at 10p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
